pipeline-prospector-insert-v1
X

Find Neurology Drugs in Phase III Clinical Development in UNITED KINGDOM

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Remimazolam

            Therapeutic Area: Neurology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals N.V.

            Deal Size: $143.2 million Upfront Cash: $11.1 million

            Deal Type: Licensing Agreement January 09, 2020

            Details:

            Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.